{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:29:28Z","timestamp":1740173368228,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Intense statin therapy was found to impair testosterone production in men. Metformin administered to subjects with hypergonadotropic hypogonadism decreased gonadotropin production. The current study was aimed at investigating whether metformin treatment modulates the impact of high-dose rosuvastatin therapy on hypothalamic\u2013pituitary\u2013testicular axis activity in men.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study included 43 very high cardiovascular risk men with late-onset hypogonadism, 20 of whom had been treated with metformin (1.7\u20133\u00a0g daily) for at least 6\u00a0months. In all subjects, unsuccessful initial statin treatment was replaced with rosuvastatin (20\u201340\u00a0mg daily). Plasma lipid levels, glucose homeostasis markers, as well as circulating levels of gonadotropins, testosterone, bioavailable testosterone, dehydroepiandrosterone-sulfate, prolactin, estradiol and creatinine were measured at the beginning of the study and 4\u00a0months later in 28 individuals in whom rosuvastatin reduced LDL cholesterol levels to below 70\u00a0mg\/dL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were no differences between treatment-induced changes in plasma lipids. In both study groups, rosuvastatin reduced total and bioavailable testosterone levels. However, only in metformin-na\u00efve men, rosuvastatin increased LH and FSH levels and slightly impaired insulin sensitivity. The impact on gonadotropin concentrations correlated with treatment-induced decrease in testosterone levels. There were no significant differences between baseline and posttreatment values of dehydroepiandrosterone-sulfate, prolactin, estradiol and the glomerular filtration rate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The obtained results suggest that metformin prevents the compensatory increase in gonadotrope function induced by intense statin therapy.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s43440-021-00289-1","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T08:03:28Z","timestamp":1622793808000},"page":"1465-1472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The impact of rosuvastatin on hypothalamic\u2013pituitary\u2013testicular axis activity in metformin-treated and metformin-na\u00efve men with low testosterone levels: a pilot study"],"prefix":"10.1007","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5454-2620","authenticated-orcid":false,"given":"Robert","family":"Krysiak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Basiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Witold","family":"Szkr\u00f3bka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogus\u0142aw","family":"Okopie\u0144","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,4]]},"reference":[{"key":"289_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000134751","volume":"13","author":"WL Miller","year":"2008","unstructured":"Miller WL. Steroidogenic enzymes. Endocr Dev. 2008;13:1\u201318.","journal-title":"Endocr Dev"},{"key":"289_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2174\/138161209787315684","volume":"15","author":"Q Zhou","year":"2009","unstructured":"Zhou Q, Liao JK. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des. 2009;15:467\u201378.","journal-title":"Curr Pharm Des"},{"key":"289_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1741-7015-11-57","volume":"11","author":"CM Schooling","year":"2013","unstructured":"Schooling CM, Au Yeung SL, Freeman G, Cowling BJ. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2013;11:57.","journal-title":"BMC Med"},{"key":"289_CR4","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/bcpt.12169","volume":"114","author":"R Krysiak","year":"2014","unstructured":"Krysiak R, Okopie\u0144 B. The effect of aggressive rosuvastatin treatment on steroid hormone production in men with coronary artery disease. Basic Clin Pharmacol Toxicol. 2014;114:330\u20135.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"289_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.pharep.2014.10.004","volume":"67","author":"R Krysiak","year":"2015","unstructured":"Krysiak R, Kowalska B, \u017bmuda W, Okopie\u0144 B. The effect of ezetimibe-statin combination on steroid hormone production in men with coronary artery disease and low cholesterol levels. Pharmacol Rep. 2015;67:305\u20139.","journal-title":"Pharmacol Rep"},{"issue":"Suppl 1","key":"289_CR6","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc21-S009","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes \u2013 2021. Diabetes Care. 2021;44(Suppl 1):S111\u201324.","journal-title":"Diabetes Care"},{"key":"289_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1055\/a-0584-0006","volume":"126","author":"R Krysiak","year":"2018","unstructured":"Krysiak R, Szkr\u00f3bka W, Okopie\u0144 B. The effect of metformin on serum gonadotropin levels in postmenopausal women with diabetes and prediabetes: a pilot study. Exp Clin Endocrinol Diabetes. 2018;126:645\u201350.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"289_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12600","author":"R Krysiak","year":"2020","unstructured":"Krysiak R, Szkr\u00f3bka W, Bednarska-Czerwi\u0144ska A, Okopie\u0144 B. Plasma gonadotropin levels in metformin-treated men with prediabetes: a non-randomized, uncontrolled pilot study. Fundam Clin Pharmacol. 2020. https:\/\/doi.org\/10.1111\/fcp.12600.","journal-title":"Fundam Clin Pharmacol"},{"key":"289_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/09513590902770172","volume":"25","author":"E Billa","year":"2009","unstructured":"Billa E, Kapolla N, Nicopoulou SC, Koukkou E, Venaki E, Milingos S, et al. Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome. Gynecol Endocrinol. 2009;25:427\u201343.","journal-title":"Gynecol Endocrinol"},{"key":"289_CR10","doi-asserted-by":"publisher","first-page":"180","DOI":"10.17305\/bjbms.2013.2359","volume":"13","author":"Z Velija-A\u0161imi","year":"2013","unstructured":"Velija-A\u0161imi Z. Evaluation of endocrine changes in women with the polycystic ovary syndrome during metformin treatment. Bosn J Basic Med Sci. 2013;13:180\u20135.","journal-title":"Bosn J Basic Med Sci"},{"key":"289_CR11","doi-asserted-by":"publisher","first-page":"35162","DOI":"10.1095\/biolreprod.110.087023","volume":"84","author":"L Tosca","year":"2011","unstructured":"Tosca L, Froment P, Rame C, McNeilly JR, McNeilly AS, Maillard V, et al. Metformin decreases GnRH- and activin-induced gonadotropin secretion in rat pituitary cells: potential involvement of adenosine 5\u02b9 monophosphate-activated protein kinase (PRKA). Biol Reprod. 2011;84:35162.","journal-title":"Biol Reprod"},{"key":"289_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrm3311","volume":"13","author":"DG Hardie","year":"2012","unstructured":"Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13:251\u201362.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"289_CR13","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/oby.2001.90","volume":"9","author":"M Ozata","year":"2001","unstructured":"Ozata M, Oktenli C, Bingol N, Ozdemir IC. The effects of metformin and diet on plasma testosterone and leptin levels in obese men. Obes Res. 2001;9:662\u20137.","journal-title":"Obes Res"},{"key":"289_CR14","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1055\/s-0035-1564070","volume":"123","author":"R Krysiak","year":"2015","unstructured":"Krysiak R, Gilowski W, Okopie\u0144 B. The effect of metformin and metformin-testosterone combination on cardiometabolic risk factors in men with late-onset hypogonadism and impaired glucose tolerance. Exp Clin Endocrinol Diabetes. 2015;123:608\u201313.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"289_CR15","first-page":"905","volume":"35","author":"O Celik","year":"2012","unstructured":"Celik O, Acbay O. Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance. J Endocrinol Invest. 2012;35:905\u201310.","journal-title":"J Endocrinol Invest"},{"key":"289_CR16","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1080\/09513590.2018.1490405","volume":"34","author":"E Seyam","year":"2018","unstructured":"Seyam E, Hefzy E. Long-term effects of combined simvastatin and metformin treatment on the clinical abnormalities and ovulation dysfunction in single young women with polycystic ovary syndrome. Gynecol Endocrinol. 2018;34:1073\u201380.","journal-title":"Gynecol Endocrinol"},{"key":"289_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1055\/s-0035-1569375","volume":"124","author":"R Krysiak","year":"2016","unstructured":"Krysiak R, Kowalcze K, Bednarska-Czerwi\u0144ska A, Okopie\u0144 B. The effect of simvastatin on plasma steroid hormone levels in metformin-treated women with non-classic congenital adrenal hyperplasia. Exp Clin Endocrinol Diabetes. 2016;124:215\u20139.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"289_CR18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412\u20139.","journal-title":"Diabetologia"},{"key":"289_CR19","first-page":"20","volume":"456","author":"B Choby","year":"2017","unstructured":"Choby B. Diabetes update: risk factors, screening, diagnosis, and prevention of type 2 diabetes. FP Essent. 2017;456:20\u20136.","journal-title":"FP Essent"},{"key":"289_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.molmed.2019.09.006","volume":"26","author":"S Wu","year":"2020","unstructured":"Wu S, Yan M, Ge R, Cheng CY. Crosstalk between Sertoli and germ cells in male fertility. Trends Mol Med. 2020;26:215\u201331.","journal-title":"Trends Mol Med"},{"key":"289_CR21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/MED.0b013e3283383031","volume":"17","author":"BB Yeap","year":"2010","unstructured":"Yeap BB. Androgens and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2010;17:269\u201376.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"289_CR22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.atherosclerosis.2009.10.037","volume":"210","author":"M Akishita","year":"2010","unstructured":"Akishita M, Hashimoto M, Ohike Y, Qgawa S, Iijima K, Eto M, et al. Low testosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors. Atherosclerosis. 2010;210:232\u20136.","journal-title":"Atherosclerosis"},{"key":"289_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/1741-7015-11-108","volume":"11","author":"L Xu","year":"2013","unstructured":"Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.","journal-title":"BMC Med"},{"key":"289_CR24","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1001\/jama.2013.280386","volume":"310","author":"R Vigen","year":"2013","unstructured":"Vigen R, O\u2019Donnell CI, Baron AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829\u201336.","journal-title":"JAMA"},{"key":"289_CR25","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1210\/jc.2011-1137","volume":"11","author":"AB Araujo","year":"2011","unstructured":"Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;11:3007\u201319.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 4","key":"289_CR26","first-page":"95","volume":"16","author":"R Krysiak","year":"2012","unstructured":"Krysiak R, Okopie\u0144 B. Chronic adrenal failure and hypergonadotropic hypogonadism in a patient with abetalipoproteinemia. Rev Med Pharmacol Sci. 2012;16(Suppl 4):95\u20137.","journal-title":"Rev Med Pharmacol Sci"},{"key":"289_CR27","doi-asserted-by":"publisher","first-page":"R235","DOI":"10.1530\/EJE-16-0927","volume":"176","author":"M L\u00f3pez","year":"2017","unstructured":"L\u00f3pez M. Hypothalamic AMPK: a golden target against obesity? Eur J Endocrinol. 2017;176:R235\u201346.","journal-title":"Eur J Endocrinol"},{"key":"289_CR28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1677\/joe.1.05844","volume":"184","author":"C Ortega-Gonz\u00e1lez","year":"2005","unstructured":"Ortega-Gonz\u00e1lez C, Cardoza L, Couti\u00f1o B, Hidalgo R, Arteaga-Troncoso G, Parra A. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. J Endocrinol. 2005;184:233\u20139.","journal-title":"J Endocrinol"},{"key":"289_CR29","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1006\/hbeh.1994.1026","volume":"28","author":"S Kawashima","year":"1994","unstructured":"Kawashima S, Takagi K. Role of sex steroids on the survival, neuritic outgrowth of neurons, and dopamine neurons in cultured preoptic area and hypothalamus. Horm Behav. 1994;28:305\u201312.","journal-title":"Horm Behav"},{"key":"289_CR30","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1210\/endo-122-6-2861","volume":"122","author":"DE Dluzen","year":"1988","unstructured":"Dluzen DE, Ramirez VD. In vivo neurotransmitter levels in the anterior pituitary of freely behaving intact and castrated male rats determined with push-pull perfusion and high pressure liquid chromatography coupled with electrochemical detection. Endocrinology. 1988;122:2861\u20134.","journal-title":"Endocrinology"},{"key":"289_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.11613\/BM.2011.031","volume":"21","author":"I Zec","year":"2011","unstructured":"Zec I, Tislaric-Medenjak D, Megla ZB, Kucak I. Anti-Mullerian hormone: a unique biochemical marker of gonadal development and fertility in humans. Biochem Med (Zagreb). 2011;21:219\u201330.","journal-title":"Biochem Med (Zagreb)"},{"key":"289_CR32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3389\/fendo.2020.00072","volume":"11","author":"G Guercio","year":"2020","unstructured":"Guercio G, Saraco N, Costanzo M, Marino R, Ramirez P, Berensztein E, et al. Estrogens in human male gonadotropin secretion and testicular physiology from infancy to late puberty. Front Endocrinol (Lausanne). 2020;11:72.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"289_CR33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1515\/hmbci-2013-0067","volume":"17","author":"KP Briski","year":"2014","unstructured":"Briski KP, Ibrahim BA, Tamrakar P. Energy metabolism and hindbrain AMPK: regulation by estradiol. Horm Mol Biol Clin Investig. 2014;17:129\u201336.","journal-title":"Horm Mol Biol Clin Investig"},{"key":"289_CR34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0006-8993(00)02763-3","volume":"879","author":"JE DeMaria","year":"2000","unstructured":"DeMaria JE, Livingstone JD, Freeman ME. Ovarian steroids influence the activity of neuroendocrine dopaminergic neurons. Brain Res. 2000;879:139\u201347.","journal-title":"Brain Res"},{"key":"289_CR35","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12933-018-0738-4","volume":"17","author":"MF van Stee","year":"2018","unstructured":"van Stee MF, de Graaf AA, Groen AK. Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. Cardiovasc Diabetol. 2018;17:94.","journal-title":"Cardiovasc Diabetol"},{"key":"289_CR36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/ije\/dyh299","volume":"34","author":"AG Barnett","year":"2005","unstructured":"Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol. 2005;34:215\u201320.","journal-title":"Int J Epidemiol"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-021-00289-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-021-00289-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-021-00289-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T14:02:10Z","timestamp":1699106530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-021-00289-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,4]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["289"],"URL":"https:\/\/doi.org\/10.1007\/s43440-021-00289-1","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"type":"print","value":"1734-1140"},{"type":"electronic","value":"2299-5684"}],"subject":[],"published":{"date-parts":[[2021,6,4]]},"assertion":[{"value":"15 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the institutional review board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}